- Home
- SNTI vs IMRN Comparison
SNTI vs IMRN Comparison
Compare SNTI & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- IMRN
- Stock Information
- Founded
- SNTI 2016
- IMRN 1994
- Country
- SNTI United States
- IMRN Australia
- Employees
- SNTI N/A
- IMRN N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- SNTI Health Care
- IMRN Health Care
- Exchange
- SNTI Nasdaq
- IMRN Nasdaq
- Market Cap
- SNTI 14.1M
- IMRN 15.0M
- IPO Year
- SNTI N/A
- IMRN N/A
- Fundamental
- Price
- SNTI $2.21
- IMRN $2.58
- Analyst Decision
- SNTI
- IMRN Strong Buy
- Analyst Count
- SNTI 0
- IMRN 1
- Target Price
- SNTI N/A
- IMRN $5.00
- AVG Volume (30 Days)
- SNTI 19.6K
- IMRN 5.7K
- Earning Date
- SNTI 11-11-2024
- IMRN 10-15-2024
- Dividend Yield
- SNTI N/A
- IMRN N/A
- EPS Growth
- SNTI N/A
- IMRN N/A
- EPS
- SNTI N/A
- IMRN N/A
- Revenue
- SNTI $338,000.00
- IMRN $3,271,194.00
- Revenue This Year
- SNTI $254.47
- IMRN N/A
- Revenue Next Year
- SNTI $169.66
- IMRN N/A
- P/E Ratio
- SNTI N/A
- IMRN N/A
- Revenue Growth
- SNTI N/A
- IMRN 171.67
- 52 Week Low
- SNTI $1.52
- IMRN $1.48
- 52 Week High
- SNTI $8.48
- IMRN $5.96
- Technical
- Relative Strength Index (RSI)
- SNTI 36.32
- IMRN 44.40
- Support Level
- SNTI $2.05
- IMRN $2.66
- Resistance Level
- SNTI $2.46
- IMRN $2.87
- Average True Range (ATR)
- SNTI 0.22
- IMRN 0.11
- MACD
- SNTI -0.08
- IMRN -0.01
- Stochastic Oscillator
- SNTI 12.90
- IMRN 26.76
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About IMRN Immuron Limited
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.